دورية أكاديمية
Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report
| العنوان: | Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report |
|---|---|
| المؤلفون: | Simon Fietz, Anne Fröhlich, Cornelia Mauch, Luka de Vos-Hillebrand, Tanja Fetter, Jennifer Landsberg, Friederike Hoffmann, Judith Sirokay |
| المصدر: | Frontiers in Immunology, Vol 14 (2023) |
| بيانات النشر: | Frontiers Media S.A. |
| سنة النشر: | 2023 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | case report, cutaneous squamous cell carcinoma, immunotherapy, anti-PD-1 antibody, cutaneous lupus erythematosus, Immunologic diseases. Allergy, RC581-607 |
| الوصف: | IntroductionThe anti-programmed cell death protein 1 (PD-1) antibody cemiplimab has shown promising results in the treatment of unresectable or metastatic squamous cell carcinoma, however, frequently leads to immune-related adverse events limiting therapy efficacy. Although cutaneous side effects are common, only very few cases of cutaneous lupus erythematosus have been reported under anti-PD-1 immunotherapy. So far, no case of cutaneous lupus has been described under treatment with cemiplimab.Case reportFor the first time, we report the case of a patient with advanced squamous cell carcinoma, who developed clinical and histological findings in sun-exposed skin that were consistent with anti-SS-A/Ro antibody-positive subacute cutaneous lupus erythematosus (SCLE) under treatment with cemiplimab. Additionally, laboratory chemical analyses revealed a severe immune-related hepatitis without clinical symptoms. Both, the SCLE and the hepatitis, resolved after the administration of topical and systemic steroids and the discontinuation of anti-PD-1 therapy.ConclusionTreatment with cemiplimab can be associated with the appearance of cutaneous lupus erythematosus in sun-exposed areas. Application of topical and systemic glucocorticoids can lead to a rapid resolution of the skin eruptions. Moreover, our case illustrates the possibility of simultaneously occurring severe immune-related adverse events. This highlights the importance of additional diagnostics to avoid overlooking additional immune-related adverse events. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1664-3224 |
| العلاقة: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1324231/fullTest; https://doaj.org/toc/1664-3224Test; https://doaj.org/article/5c65c93846d04e19a86da137502b47bdTest |
| DOI: | 10.3389/fimmu.2023.1324231 |
| الإتاحة: | https://doi.org/10.3389/fimmu.2023.1324231Test https://doaj.org/article/5c65c93846d04e19a86da137502b47bdTest |
| رقم الانضمام: | edsbas.ACA7E390 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 16643224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1324231 |